drugset / Trial / NCT00507403
Infliximab and Methotrexate in Ankylosing Spondylitis
Phase 4
Completed
30 enrolled
University Hospital, Tours
Institut National de la Santé Et de la Recherche Médicale, France · collab
RandomizedParallel-groupOpen-labelDiagnostic
Summary
There is a great individual variability of pharmacokinetic of infliximab in patients treated for ankylosing spondylitis (AS). Moreover, some patients have a treatment with methotrexate (MTX), others have not. Thus, the aim of this study is to assess the effect of MTX on the pharmacokinetic properties of infliximab in 30 patients treated for AS, 15 with MTX, 15 without.
Timeline
- Start
- 2007-10
- Primary completion
- 2009-10
- Completion
- 2009-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Infliximab | Monoclonal antibody | 5 mg/kg | — |